Senior Consultant in Anaesthesia and Intensive Care Medicine at the Royal Free London NHS Trust.
Critical care anaesthesiologist at Royal Free hospital.
Medical Practitioner and passionate about longevity and the future of health.
Yadhu is a world leader in personalised Medicine and has a real passion for helping people live the best life.
Prof. Dr. Rajiv Jalan
Leading consultant hepatologist with more than 30 years of experience.
Professor of Hepatology at University College London, Institute for Liver and Digestive Health, Royal Free Hospital.
Head of the Liver Unit at the Royal Free Hospital, London U.K
Editor in chief of one of the most important Medical journals on Liver health in the world.
Prof. Em. Dr. Amina Ather
Scientific Director, MPR, Germany,
PhD Public Health, Post Graduate diploma in genetic sciences and gene therapy – EIH, Doctor of Medicine (RGUHS),
Representative for ASIAN countries, European Medical Association.
Post Graduate diploma in microbiology and computing application (FORD FOUNDATION) Regenerative medicine (USM). Fellowship in empowerment by ICT, gender and health (NIEW), Women empowerment (NAM), clinical trials – WHO.
Ambassador for RED CROSS, “first aid for mental trauma”, Jury – UNESCO - Sustainable development goals.
Dr. Jaroslav Boublik
B.Sc. (Hons) from the Department of Chemistry, Monash University.
Published over 30 peer reviewed and invited articles in scientific journals.
Presented almost 40 scientific papers at research symposia, and is an inventor on four patents.
Nutritional adviser to several elite athletes, including Olympic medalists.
Developed dozens of new products for client companies in nutrition, sports performance, hydration and functional foods.
As former CEO of Holland Barrett and Chairman of the HFMA, Health Food Manufacturers Association
Peter Aldis is one of the biggest names in the UK health food industry, and one of the most visible retail business leaders in the country. During his tenure as CEO, Holland & Barrett established itself as a leader in product innovation, with a series of bold launches into new categories like ‘clean beauty’. Under his leadership the company significantly expanded its international presence and delivered 39 consecutive quarters of like-for-like growth
CEO of Redbull UK from 1999 - 2000. Grew Red Bull from £12m loss to £450m in profits.
Head of Europe for Anheuser- Busch Launched Budweiser in Europe.
Created Bud Light amongst other brands for Anheuser-Busch.
Acquired Maison Caurette and grew Sol Beer to become UK leader.
Head of Marketing for Ernest and Julio Gallo (largest family owned winery in USA).
Top UK Strategic Consultant.
Grew Veuve Clicquot from 300,000 bottles to 2.3 million bottles per year.
Grew Boodles Jewellers from a turnover of £7m to £60m.
Grew Links of London from one to twenty three retail outlets.
Key strategic consultant for Redbull.
Has grown over £1 billion in revenues for client companies.
Former CEO of Asda / Walmart.
Chairman of Leeds Bradford airport.
Chairman of Newton Group.
Chairman of Spoon Guru.
Chairman of Immodulon therapeutics.
Board advisor of AMP Capital.
Suhail Al Ansari
Founding & Managing Partner at Biolinka Investments LLC Biolinka).
Executive Director at Mubadala Investment Company (Mubadala).
Vice Chairman at the Cleveland Clinic Abu Dhabi.
Chairman of the Board of Directors of The Imperial College London Diabetes Centre, Healthpoint Hospital, National Reference Laboratory, Tawam Molecular Imaging Centre, Capital Health Screening Centre, Abu Dhabi.
Dr. David Ramm focuses his practice on private equity, venture capital and M&A transactions in the technology sector. David helps clients raise significant capital throughout their fundraising cycle, grow their businesses through commercial transactions, joint ventures and licensing, and progress to exit, either by sale or IPO. David represents both companies on the growth path and the investors that support them. He has over 20 years of experience assisting creative and IP-rich businesses, particularly in the life sciences, healthcare, financial services and security sectors, in corporate finance, M&A and commercial transactions. Many of the transactions that David assists clients with have a cross-border, or multi-jurisdictional, component.
David’s clients include large financial institutions and companies at the forefront of technological development, as well as exciting early stage and growth companies in the life sciences, healthcare, fintech and security industries. As a former PhD scientist and engineer, David brings a unique perspective to the practice of law in the technology sector.